3. PARPi monotherapy had no negative effect on subsequent
platinum-based chemotherapy and could improve prognosis.
27 patients with a median PFI of 20.2 months were treated with
subsequent platinum-based chemotherapy after PARPi progression, and were
enrolled in study group 2 ; Among the 23 patients in the control group
without PARPi history, PFI of 22 patients after third-line
platinum-based chemotherapy was obtained, including 14
platinum-sensitive relapsed patients (PFI≥6 months), 13 of whom
underwent subsequent platinum-based chemotherapy (Control group 2), and
8 platinum-resistant relapsed patients (PFI<6 months, Control
group 3). The baseline characteristics of the patients were shown in
Table 2 and
Table
S3. We compared the TFST of patients with platinum-based chemotherapy
after the progression of PARPi and with patients in control group 2, and
the result showed no statistical difference (Figure 2C; mTFST: 7.5 vs.
7.1 months, HR=1.11, p=0.800). Further survival analysis showed that PRS
of patients in study group 2 was similar to platinum-sensitive relapse
patients after third-line platinum chemotherapy (Figure 2D; mPRS: NR vs.
42.2 months, HR=0.66, p=0.503), and superior to platinum-resistant
relapse patients after third-line platinum chemotherapy (Figure 2D;
mPRS: NR vs. 23.7 months, HR=0.15, p=0.009).